Gilead acquired global rights to Genhouse Bio’s MAT2A-targeting cancer candidate (GH31), paying $80 million upfront and up to $1.45 billion in milestones. Genhouse has secured IND clearance in both China and the U.S. to begin clinical testing of GH31. Gilead framed the transaction as disciplined pipeline expansion in oncology; Genhouse’s leadership said the deal validates the global potential of its synthetic lethal platform. The asset strengthens Gilead’s synthetic-lethality portfolio after other recent deals and reflects Big Pharma’s appetite for clinic-ready oncology candidates from Chinese biotech. The structure—substantial milestones and double-digit royalties—signals how major pharmas are de‑risking external oncology R&D while securing international development pathways.